SIR,-I would like to point out the great significance of the case report published by P Corridan et al. ' They describe a patient who developed an acute angle-closure attack as a rare complication of periocular botulinum toxin (BoTx) for blepharospasm.
As regards the pupillary effects of BoTx, it was Carl Kupfer' who first reported that retrobulbar injection of BoTx in rabbits produces mydriasis, probably by affecting the ciliary ganglion. However, very high doses were used in his study,2 and in order to prevent lethal complications anti-BoTx antibodies were injected into all the animals. In contrast to the lethal doses used by Kupfer9 we injected nonlethal doses of BoTx into the right orbit of rats (between 1 5 ng-2-5 ng BoTx). All SIR,-In our study of lens biometry in earlyonset diabetes one of our objectives was to provide a precise statement concerning the effects on the lens of 'true' diabetic duration.' Information on disease duration of 'late-onset' diabetes is frequently inaccurate, and for this reason a strict definition of 'early onset' diabetes was applied in our study. Our information on 'true' diabetic duration was therefore reasonably precise. Among the early-onset diabetics we found that, for all but one of the lens biometric features measured, age and diabetic duration were the most important determinants of lens biometry. In our multiple regression analysis we fixed the age slope in the diabetic subgroup to that of the non-diabetic control group prior to fitting the duration regression term. The slope of our duration term therefore represents the additional effect of diabetic duration over and above the normal aging effect. Our methods thus provide the most precise estimate available of the effect of 'true' diabetic duration on lens biometry.
Fledelius et al take issue with our statement that 'this report is the first in which a precise assessment of the effect of "true" diabetic duration on lens biometry has been possible.' In their paper, however, they provide no information regarding the diabetic type of the patients included in their study.2 The reader is therefore left ignorant as to whether the 'true' diabetic duration of their patients was known. It is apparent only from their present communication that the patients in their study were mostly early-onset diabetics, with 'a few type 2 diabetics' included.
Fledelius et al employed a statistical method which demonstrated an effect of diabetic duration. Their method did not, however, provide 'a precise assessment of the effect of "true" diabetic duration on lens biometry.' In their method they calculated: 'individual lens thickness deviation values (in %), with + or -to signify higher or lower than expected according to non-diabetic regression line values for actual age and sex.' Using these calculated 'percentage deviation values' they then performed a second regression analysis against diabetic duration. Their method is acceptable for determining whether there is a duration effect or not, but it certainly has not provided 'a precise assessment of the effect of diabetic duration.' In fact, the regression coefficient quoted in their paper is a rather meaningless statistic, and does not provide the reader with any sort of useful estimate of the impact per year of diabetic duration on lens thickness. (Their reason for using a 'percentage deviation value' is unclear, as this would have the effect of distorting the magnitude of their duration effect, and implies an a priori belief that the impact of diabetic duration varies with the size of the lens.)
Our statement therefore is defensible, firstly, because no information regarding type of diabetes was provided by Fledelius et al in their paper,2 and, secondly, because the
